ATRA plus KPD for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of all-trans retinoic acid (a form of vitamin A) with a chemotherapy regimen called KPD for patients whose multiple myeloma has come back or is not responding to standard treatments. The goal is to see if this combination can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your multiple myeloma has come back or is not responding to treatment.
- You have measurable disease (myeloma protein in blood or urine, or abnormal free light chain levels).
- You are in good physical condition (ECOG score 0-2) and expected to live at least 3 months.
- You have not had other cancer treatment within the last 2 weeks, and your blood counts, heart, lungs, liver, and kidneys are within acceptable limits.
- You are not pregnant, breastfeeding, or have other serious uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
This trial tests if combining the drug ATRA with carfilzomib can help people with multiple myeloma whose cancer has come back or stopped responding to at least three prior treatments, including carfilzomib. The goal is to see if this new combination works better than carfilzomib alone.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
This trial tests a combination of three drugs (mezigdomide, carfilzomib, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if this new drug mix can help control the cancer again.
This trial tests a new way to treat multiple myeloma after a stem cell transplant. It uses a combination of drugs (KPD) to help keep the disease from coming back.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.